Abstract

Objectives: This session will review the evolving scientific understanding of incretin-based therapies, with a focus on GIP (Glucose-dependent Insulinotropic Polypeptide). Emerging clinical data on the role of GIP in advancing the treatment landscape of obesity and other weight-related co-morbidities will be reviewed. Introduction: Advances in incretin-based therapies have led to the development of dual Glucose-dependent Insulinotropic Polypeptide (GIP)/Glucagon-like peptide-1 (GLP-1) receptor agonists, representing a new frontier in obesity management. While GLP-1 receptor agonists have shown clinical success, the addition of GIP to a GLP-1 receptor agonistsmay offer synergistic benefits through distinct and complementary mechanisms that may enhance treatment outcomes. Materials / method: The emerging role of GIP in obesity and obesity-related comorbidities will be reviewed. Results: GIP acts on multiple tissues, notably adipose tissue where it contributes directly to improved lipid buffering capacity and body composition. In the central nervous system, GIP may synergistically reduce food intake while attenuating GLP-1-induced nausea, potentially improving overall tolerability. Therapies which target dual incretin receptors appear to potentially overcome efficacy limitations which may be seen with selective with GLP-1 monotherapy. Conclusion: Efficacy data using Glucose-dependent Insulinotropic Polypeptide (GIP)/Glucagon-like peptide-1 (GLP-1) receptor agonists have led to a resurgence of research on the fascinating and emerging role of GIP in obesity